- Home
- AUGX
AUGX
Augmedix Inc.
as 05-20-2024 4:00pm EST
Augmedix Inc is engaged in ambulatory/clinical/hospital segments of the U.S. patient care services market with products that address medical note documentation needs. The company's products cater to large and small healthcare organizations but can also be adopted by individual practitioners. The company products extract data from natural clinician-patient conversations and convert it in real time to medical notes, which are seamlessly transferred to the electronic health record (EHR). The company's revenues consist of service fees charged to its customers to subscribe to the company's remote medical documentation and clinical support products.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 59.3M | IPO Year: | N/A |
| Target Price: | $5.00 | AVG Volume (30 days): | 639.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.99 - $6.25 | Next Earning Date: | 05-13-2024 |
| Revenue: | $48,698,000 | Revenue Growth: | 45.04% |
| Revenue Growth (this year): | 38.66% | Revenue Growth (next year): | 38.78% |
Share on Social Networks:
Stock Insider Trading Activity of Augmedix Inc. (AUGX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Shakil Ian | AUGX | CHIEF STRATEGY OFFICER | Apr 15 '24 | Sell | $3.80 | 500 | $1,900.00 | 3,000 | SEC Form 4 |
| Shakil Ian | AUGX | CHIEF STRATEGY OFFICER | Apr 12 '24 | Sell | $3.82 | 19,544 | $74,589.68 | 3,000 | SEC Form 4 |
| Shakil Ian | AUGX | CHIEF STRATEGY OFFICER | Apr 9 '24 | Sell | $4.14 | 31,542 | $130,520.80 | 3,000 | SEC Form 4 |
| Shakil Ian | AUGX | CHIEF STRATEGY OFFICER | Apr 9 '24 | Sell | $3.87 | 36,467 | $141,287.74 | 3,000 | SEC Form 4 |
| Shakil Ian | AUGX | CHIEF STRATEGY OFFICER | Apr 9 '24 | Sell | $3.93 | 24,778 | $97,476.65 | 3,000 | SEC Form 4 |
| Shakil Ian | AUGX | CHIEF STRATEGY OFFICER | Apr 5 '24 | Sell | $4.03 | 51,387 | $207,233.49 | 12,217 | SEC Form 4 |
| Shakil Ian | AUGX | CHIEF STRATEGY OFFICER | Apr 5 '24 | Sell | $3.97 | 28,563 | $113,380.83 | 12,217 | SEC Form 4 |
| Shakil Ian | AUGX | CHIEF STRATEGY OFFICER | Apr 5 '24 | Sell | $3.97 | 9,217 | $36,586.88 | 3,000 | SEC Form 4 |
| Shakil Ian | AUGX | CHIEF STRATEGY OFFICER | Apr 3 '24 | Sell | $4.11 | 45,906 | $188,600.21 | 95,665 | SEC Form 4 |
| Shakil Ian | AUGX | CHIEF STRATEGY OFFICER | Apr 3 '24 | Sell | $4.15 | 64,055 | $265,853.87 | 31,610 | SEC Form 4 |
| Shakil Ian | AUGX | CHIEF STRATEGY OFFICER | Apr 1 '24 | Sell | $3.89 | 51,346 | $199,684.59 | 187,666 | SEC Form 4 |
| Shakil Ian | AUGX | CHIEF STRATEGY OFFICER | Apr 1 '24 | Sell | $4.02 | 7,632 | $30,698.96 | 180,034 | SEC Form 4 |
| Shakil Ian | AUGX | CHIEF STRATEGY OFFICER | Apr 1 '24 | Sell | $3.89 | 38,463 | $149,724.92 | 141,571 | SEC Form 4 |
| Shakil Ian | AUGX | CHIEF STRATEGY OFFICER | Mar 28 '24 | Sell | $4.06 | 31,994 | $129,850.85 | 219,660 | SEC Form 4 |
| Shakil Ian | AUGX | CHIEF STRATEGY OFFICER | Mar 28 '24 | Sell | $4.06 | 31,994 | $129,850.85 | 187,666 | SEC Form 4 |
Latest Augmedix Inc. News
AUGX Breaking Stock News: Dive into AUGX Ticker-Specific Updates for Smart Investing
Thomson Reuters StreetEvents
6 days ago
Q1 2024 Augmedix Inc Earnings Call
MT Newswires
6 days ago
Maxim Downgrades Augmedix to Hold From Buy
GuruFocus.com
7 days ago
Augmedix Inc (AUGX) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth Amidst Challenges
GlobeNewswire
7 days ago
Augmedix Delivers 40% Revenue Growth for First Quarter of 2024
GlobeNewswire
17 days ago
Augmedix to Participate in Upcoming Investor Conferences in May and June 2024
GlobeNewswire
20 days ago
Augmedix to Announce First Quarter 2024 Financial Results on May 13, 2024
GlobeNewswire
25 days ago
Augmedix Awarded on Newsweek’s World’s Best Digital Health Companies 2024 List
GlobeNewswire
a month ago